Lubrizol Announces an Important Milestone for Its Novel Patented Excipient, Apisolex™ Polymer

CLEVELAND, Ohio — Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials.

Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class II and IV active pharmaceutical ingredients (API). Apisolex polymer excipient is manufactured following Good Manufacturing Practices (GMP) guidelines and can be used in dosage forms for various routes of administration, including parenteral.

The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold. Apisolex polymer excipient is currently being evaluated in multiple programs across the globe, enabling delivery of hard-to-formulate APIs from various therapeutic classes and by multiple routes.

Kevin Song, Senior Director, Global Pharmaceutical and Nutraceutical Business, notes "the progression to clinical trials of a medicinal product formulated with Apisolex polymer excipient demonstrates its ability to provide differentiated solutions to solubility and bioavailability challenges in parenteral formulations." Song adds, "Lubrizol continues to invest in expanding the reach of the Apisolex polymer excipient across global markets and nurturing relationships with drug product manufacturers that are facing insoluble API challenges."

关于路博润

隶属于伯克希尔哈撒韦的路博润公司是一家科技公司，其特种化学品为推动交通发展、增进人们福祉并提升现代生活品质提供可持续的解决方案。每天，路博润的创新者们都在科学、市场需求和商业成功的交汇点上努力为客户创造非凡价值，推动探索并创造突破性解决方案，从而改善生活，让世界运转得更好。路博润成立于1928年，业务足迹遍布本地和全球，在全世界拥有超过100家制造工厂、销售和技术办事处以及超过7,000名员工。 了解更多信息，请访问 www.Lubrizol.com。

新闻类别：<a href=/Newscenter/News-and-Insights?category=Health>健康</a>